Clinical Trials

55 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06856499 2026-06-04

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

50 enrolled

Fallopian Tube Neoplasms

NCT03842228 2026-05-29

COD

39 enrolled 15 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT05411094 2026-05-29

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Phase 1 Suspended

18 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06177171 2026-05-27

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

18 enrolled

BRCA1 Mutation

NCT02308072 2026-05-22

ORCA-2

Phase 1 Completed

16 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT04633239 2026-05-22

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

42 enrolled

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT02264678 2026-05-12

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

354 enrolled

Ovarian Neoplasms

NCT00777582 2026-05-08

Phase I Comparative Bioavailability Study

197 enrolled

Other solid neoplasm

Solid Tumors

NCT07371104 2026-05-08

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

40 enrolled

Neoplasms, Ovarian Neoplasms

NCT04197713 2026-04-29

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

13 enrolled 13 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT06545942 2026-04-17

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

220 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03162627 2026-04-15

Selumetinib and Olaparib in Solid Tumors

EndocrineNETOther solid neoplasmThoracic

90 enrolled

Breast

Breast Neoplasms

NCT04375267 2026-04-14

LuPARP

Phase 1 Completed

18 enrolled

Mesothelioma, Thymoma, Neuroendocrine Tumors

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

BreastGastrointestinalGynecologic

604 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT06130254 2026-04-09

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Phase 1 Terminated

1 enrolled

Other solid neoplasmThoracic

Advanced Solid Tumor

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

25 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03742245 2026-03-16

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer